Skip to main content

Biopharma

Radiopharma & Theranostics Asia Congress 2028

Date
18–19 April 2028
Location
Seoul, South Korea

Event details coming soon

The programme, speakers and registration details for this conference are being finalised. Register your interest and we will send them through as soon as they are confirmed.

Register your interest

INSIGHTS

  • BiopharmaMarket insight

    APAC’s Radiopharmaceutical Landscape Is Taking Shape: Where Are the Next Hubs Emerging?

    Asia-Pacific’s radiopharmaceutical sector is expanding as countries invest in isotope production, drug development, specialised manufacturing and theranostics infrastructure. This article examines how Australia, China, Japan, South Korea, India, Singapore and Southeast Asia are developing distinct roles within an increasingly interconnected regional ecosystem.

    Read more: APAC’s Radiopharmaceutical Landscape Is Taking Shape: Where Are the Next Hubs Emerging?
  • BiopharmaIndustry article

    Eppendorf Breaks Ground on a EUR 40 Million Production Site in Penang, Malaysia

    On 12 November 2026, Eppendorf SE broke ground on a new production facility at Bandar Cassia Technology Park in Penang. The EUR 40 million investment is the company's first manufacturing operation in Southeast Asia and will produce selected products from its Centrifuges & Instruments portfolio for laboratories worldwide, with production starting gradually in 2028.

    Read more: Eppendorf Breaks Ground on a EUR 40 Million Production Site in Penang, Malaysia
  • BiopharmaMarket insight

    Genome Editing in Asia: Can the Region Turn CRISPR Science into Accessible Therapies?

    The first approved CRISPR therapy proved that genome editing can work as a medicine. Asia, home to a large share of the world's patients with inherited blood disorders and a fast-growing research base, is now moving from discovery towards the clinic. This article looks at where the region stands, what is holding it back and what to watch next.

    Read more: Genome Editing in Asia: Can the Region Turn CRISPR Science into Accessible Therapies?